Nasdaq Immx News Today

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 316,600 shares, a growth of 19.9% from the February 29th total of 264,100 shares. Based on an average daily trading volume, of 289,400 […]

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) saw a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 489,900 shares, an increase of 123.2% from the January 15th total of 219,500 shares. Currently, 6.4% of the shares of the stock are sold short. Based […]

LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage...

LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage...

Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to...

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) saw a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 172,200 shares, an increase of 71.7% from the September 30th total of 100,300 shares. Approximately 2.3% of the shares of the company are sold short. Based […]

Immix Biopharma (NASDAQ:IMMX – Get Free Report) is one of 888 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Immix Biopharma to related businesses based on the strength of its valuation, risk, analyst recommendations, dividends, institutional ownership, profitability and earnings. Volatility and Risk […]

Immix Biopharma (NASDAQ:IMMX – Get Free Report) is one of 975 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Immix Biopharma to related businesses based on the strength of its analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership. Volatility & Risk Immix Biopharma […]

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) Director Melissa Jane Buchan purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was acquired at an average cost of $2.46 per share, with a total value of $49,200.00. Following the purchase, the director now directly owns 20,000 […]

LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage...